Pulvirenti D, Aikaterini T, Campagna A, Ignaccolo L, Giustolisi N, Costa E
Medicina Interna, Policlinico Universitario, Catania, Italia.
Clin Ter. 2008 Sep-Oct;159(5):307-10.
Hyperparathyroidism is a generalized alteration of calcium, phosphorus and bone metabolism due to an increased secretion of parathyroid hormone (PTH). In addition to the paraneoplastic ectopic type, we can distinguish three eutopic types of hyperparathyroidism, i.e., the primary form, mostly due to a benign or malignant tumor of parathyroid gland, the secondary form, typical of kidney disease and tertiary form, due to the progression of secondary forms. There is not agreement, in medical literature, on the treatment of these patients. To establish the correct therapeutic approach in patients with hyperparathyroidism, we have followed a group of symptomatic subjects suffering from primary, secondary and tertiary hyperparathyroidism, taking into account the therapeutic needs.
We followed for 12 months 155 patients suffering from primary, secondary and tertiary hyperparathyroidism; 82 were in end stage kidney disease, 93 were hypertensive. Subjects with primary forms has been treated, before parathyroidectomy, with hydration (physiological solution of NaCl), bisphosphonates i.v. (pamidronate 60-90 mg in 4-6h) and, if serum calcium was higher than 12 mg/dl, loop diuretics (furosemide 40 mg/day). Subjects with secondary forms has been treated with hypo-phosphoric diet, phosphate bindings (calcium carbonate 1 g/day) and oral calcitriol (1 microg/d) before subtotal parathyroidectomy. After surgery it was administered support therapy with calcium gluconate (40 ml/day) and vitamin D (2.5mg/d) until serum calcium normalization.
There were 55 cases of post surgery hypertensive attack treated with clonidine (300 microg/d); 8 months later there was not relapses but in all patients there was reduction of serum calcium concentration that required a substitutive treatment (calcium 1 g/day and calcitriol 1 microg/day). There was 1 case of heavy hypocalcemic state treated with calcium gluconate i.v. (40 ml/day).
A correct approach to a non-paraneoplastic hyper-parathyroid patient need of an integration of both current medical and surgical options. In primary forms the fi rst option is the surgical approach supported by medical treatment. In secondary forms medical approach is preferable to control renal and vascular complications, while surgical therapy is to prefer in non-responders to medical therapy forms.
甲状旁腺功能亢进是由于甲状旁腺激素(PTH)分泌增加导致的钙、磷和骨代谢的全身性改变。除了副肿瘤异位型,我们可以区分三种原位甲状旁腺功能亢进类型,即原发性,主要由甲状旁腺的良性或恶性肿瘤引起;继发性,典型于肾脏疾病;以及三发性,由继发性类型进展而来。医学文献中对于这些患者的治疗尚无共识。为了确定甲状旁腺功能亢进患者的正确治疗方法,我们根据治疗需求,对一组患有原发性、继发性和三发性甲状旁腺功能亢进的有症状患者进行了跟踪研究。
我们对155例患有原发性、继发性和三发性甲状旁腺功能亢进的患者进行了12个月的跟踪研究;其中82例处于终末期肾病,93例患有高血压。原发性甲状旁腺功能亢进患者在甲状旁腺切除术前接受了补液(生理盐水)、静脉注射双膦酸盐(帕米膦酸60 - 90毫克,4 - 6小时内)治疗,并且如果血清钙高于12毫克/分升,则使用袢利尿剂(速尿40毫克/天)。继发性甲状旁腺功能亢进患者在次全甲状旁腺切除术前接受了低磷饮食、磷结合剂(碳酸钙1克/天)和口服骨化三醇(1微克/天)治疗。术后给予葡萄糖酸钙(40毫升/天)和维生素D(2.5毫克/天)的支持治疗,直至血清钙恢复正常。
有55例术后高血压发作患者接受了可乐定治疗(300微克/天);8个月后未复发,但所有患者的血清钙浓度均降低,需要替代治疗(钙1克/天和骨化三醇1微克/天)。有1例严重低钙血症患者接受了静脉注射葡萄糖酸钙治疗(40毫升/天)。
对于非副肿瘤性甲状旁腺功能亢进患者,正确的治疗方法需要结合当前的药物和手术选择。在原发性甲状旁腺功能亢进中,首选手术方法并辅以药物治疗。在继发性甲状旁腺功能亢进中,药物治疗更适合控制肾脏和血管并发症,而对于药物治疗无反应的类型则首选手术治疗。